DOSAGE INDEX / BLEND
Tri-Heal
Research, reported schedules and supply planning.
Review Tri-Heal through the BPC-157/TB-500 pair and KPV research, identifying the comparisons needed to support a three-component healing claim.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 0.5–4 mg total blend per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
The source assumes TB-500:BPC-157:KPV amounts of 25:10:10 mg per vial. Independent validation of the combined regimen has not been established.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 45 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
Studies of individual ingredients do not establish the effects of this finished combination. Combination studies are identified explicitly below.
- The reference catalog lists Tri-Heal as TB-500, BPC-157 and KPV. The name identifies a marketed mixture; it does not establish a measured healing outcome. A directly matched primary outcome study of the exact three-component formula was not established in this selected search.
- A 2026 rat Achilles study found no added benefit from the tested BPC-157/TB-500 combination. KPV was not part of that experiment. [1]
- KPV has original evidence from intestinal inflammation models, including reduced inflammatory changes in mice with experimental colitis. Those studies did not test the Tri-Heal formulation. [2]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 12 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original study
- Original KPV mouse study
- Annals of the New York Academy of Sciences (2012)Further reading · Listed in reference bibliography.
- HSS Journal / PMC (2025)Further reading · Listed in reference bibliography.
- Molecular Therapy Methods & Clinical Development / PMC (2017)Further reading · Listed in reference bibliography.
- Clinical Chemistry (2016)No destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- CDC Pink Book (2024)No destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- Frontiers in Endocrinology (2021)Further reading · Listed in reference bibliography.
- Current Reviews in Musculoskeletal Medicine (2025)Further reading · Listed in reference bibliography.
- Journal of Orthopaedic Research (2003)Further reading · Listed in reference bibliography.
- CDC (Subcutaneous Injection PDF)General guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Subcutaneous Drug Injection Review / PMCFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.